Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

What happened

Hengrui Pharma reported first nine months of 2026 revenue of RMB24.41 billion, up 5.26% year-over-year, and net profit attributable to shareholders of RMB6.92 billion, up 20.38%, with innovative drug sales reaching RMB13.87 billion, up 17.05%.

Confirmed

Global impact / market context

Profit grew much faster than revenue because innovative drug sales, which carry higher profit per sale, rose 17.05% and made up about 64.59% of total drug sales, shifting the sales mix toward newer medicines.

Analyst inference

Third-quarter revenue rose 20.55% and net profit rose 88.92% year-over-year, showing growth sped up late in the period while R&D spending of RMB7.15 billion, with RMB5.42 billion expensed, weighed on costs.

Analyst inference

What to watch

1. Hengrui obtained seven innovative drug or indication approvals in the third quarter of 2026, comprising two Class 1 innovative drugs and five new indications for marketed innovative drugs. Confirmed
2. Watch whether the seven accepted marketing applications, which are requests for approval to sell a drug, convert into sales and add revenue in coming quarters. Proposed
3. Track non-oncology innovative drug sales, which reached RMB4.01 billion, up 75.36%, because continued growth here would further shift the sales mix toward higher-profit products. Analyst inference

Evidence

• Original source link unavailable